Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03076437
Recruitment Status : Recruiting
First Posted : March 10, 2017
Last Update Posted : March 10, 2017
Sponsor:
Collaborator:
Dongguan People's Hospital
Information provided by (Responsible Party):
Shenzhen Institute for Innovation and Translational Medicine

Brief Summary:

Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor (CAR) will be infused back to patients with B cell malignancies, including lymphoma and leukemia. The patients will be monitored after infusion of anti-CD19 CAR-transduced T cells for adverse events, persistence of anti-CD19 CAR-transduced T cells and treatment efficacy.

Objectives:

To evaluate the safety and the efficacy of anti-CD19 CAR-transduced T cell therapy for patients with B cell malignancies.

Eligibility:

Patients between 1 and 80 years of age, who have relapsed or refractory CD19-expressing B-cell malignancies (leukemia or lymphoma) that have not responded to standard treatments.

Patients with a history of allogeneic stem cell transplant who meet all eligibility criteria are eligible to participate.

Patients must have adequate organ functions.

Design:

Peripheral blood from patients will be collected for isolation of peripheral blood mononuclear cells (PBMCs), which will be transduced with a lentiviral or retroviral vector encoding anti-CD19 CAR containing a CD28 or 4-1BB and a CD3 zeta as costimulatory domains.

Patients will receive a lymphodepleting preconditioning regimen to prepare their immune system to accept modified T cells.

Patients will receive an infusion of their own modified T cells. They will remain in the hospital to be monitored for adverse events until they have recovered from the treatment.

Patients will have frequent follow-up visits to monitor the persistence of modified T cells and efficacy of the treatment.


Condition or disease Intervention/treatment Phase
Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Lymphoma Combination Product: Drugs and Anti-CD19-CAR transduced T cells Phase 1 Phase 2

Detailed Description:

Despite progress has been made to date in the treatment of patients with B cell malignancies, including leukemia and lymphoma, many patients with relapsed or refractory diseases do not respond to the standard treatments. It has been shown that anti-CD19 CAR-transduced T cells may be an effective approach to treat the relapsed or refractory diseases. The procedure involves collecting PBMCs from the patients and modifying the T cells to attack the malignant B cells. In this trial, autologous T cells engineered to express an anti-CD19 chimeric antigen receptor (CAR) containing the signaling domains of CD28 or 4-1BB and CD3-zeta will be infused back to patients with B cell malignancies, including lymphoma and leukemia. The patients will be pretreated with a lymphodepleting preconditioning regimen before the infusion of anti-CD19 CAR T cells, and will be monitored for adverse events, persistence of anti-CD19 CAR-transduced T cells and the treatment efficacy.

OBJECTIVES:

Primary objectives:

To determine the safety and feasibility of the administration of anti-CD19 CAR transduced T cells in patients with CD19+ B-cell malignancies.

Secondary objectives:

To determine if the treatment regimen can result in clinical regression of B-cell malignancies in the patients as described above.

To determine the in vivo persistency of the anti-CD19 CAR-transduced T cells.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Actual Study Start Date : January 15, 2016
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2019


Arm Intervention/treatment
Experimental: Anti-CD19-CAR transduced T cells

Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.

Interventions:

Drug: Fludarabine Drug: Cyclophosphamide Biological: Anti-CD19-CAR transduced T cells

Combination Product: Drugs and Anti-CD19-CAR transduced T cells

Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.

Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine).





Primary Outcome Measures :
  1. Number of participants with Adverse Events [ Time Frame: 8 weeks ]
    To evaluate the safety and feasibility of the administration of anti-CD19 CAR transduced T cells in patients with CD19+ B-cell malignancies.


Secondary Outcome Measures :
  1. Number of participants with Clinical responses [ Time Frame: 2 years ]
    To determine if the treatment regimen can result in clinical regression of B-cell malignancies in the patients as described above.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have a CD19+ B cell malignancy,including relapsed or refractory B cell leukemia and B cell lymphoma;
  2. Patients with CD19+ B cell malignancies are not able to receive standard treatments and willing to participate in the trial;
  3. Patients must have a measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis;
  4. patients are not eligible for autologous or allogeneic stem-cell transplantation (SCT) or relapsed after autologous or allogeneic stem-cell transplantation;
  5. Patients with history of allogeneic stem cell transplantation are eligible, providing 6 months had elapsed from SCT, they have no evidence of active graft-versus-host disease and no longer taking immunosuppressive agents during the treatment.
  6. Willing to sign a durable power of attorney;
  7. Able to understand and sign the Informed Consent Document;
  8. Performance status:ECOG 0-2;
  9. Life expectancy:More than 3 months;
  10. Patients of both genders must be willing to practice birth control for four months after receiving a lymphodepleting preconditioning regimen;
  11. Female participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion, because of the potentially dangerous effects on the fetus;
  12. There is no obvious dysfunctions in heart , liver and kidney, and the functions of vital organs are normal;
  13. Serology: (1) Seronegative for HIV antibody; (2) Seronegative for hepatitis B virus (HBV) and hepatitis C virus (HCV).
  14. More than three weeks must have elapsed since any prior systemic therapy at the time of randomization, and patients' toxicities must have recovered to a grade 1 or less (except for alopecia or vitiligo);
  15. Normal cardiac ejection fraction and no evidence of pericardial effusion as determined by an echocardiogram;
  16. More than 30 days must have elapsed since Monoclonal antibody therapy administered prior to apheresis.

Exclusion Criteria:

  1. Patients that require urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression;
  2. Patients that have active hemolytic anemia;
  3. Patients with detectable cerebrospinal fluid malignant cells or brain metastases or with a history of cerebrospinal fluid malignant cells or brain metastases, or any residual intracranial implants;
  4. Women of child-bearing potential who are pregnant or breastfeeding;
  5. Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system;
  6. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease);
  7. Concurrent opportunistic infections;
  8. Concurrent Systemic steroid therapy;
  9. History of severe immediate hypersensitivity reaction to any of the agents used in this study;
  10. Patients with central nervous system (CNS) metastases or symptomatic CNS involvement (including cranial neuropathies or mass lesions);
  11. CNS-3 disease or traumatic spinal tap with POSITIVE Steinherz/Bleyer algorithm with cerebral spinal fluid involvement with malignancy will make any patient not eligible for this protocol;
  12. Patients with cardiac atrial or cardiac ventricular lymphoma involvement;
  13. Other anti-neoplastic investigational agents currently or within 30 days prior to start of the treatment;
  14. Previous treatment with any gene therapy products.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03076437


Contacts
Layout table for location contacts
Contact: Mingjun Wang, MD,PhD 15814723218 mingjunw429@163.com
Contact: Yirong Jiang, MD 13688967985 dgjyr0769@163.com

Locations
Layout table for location information
China, Guangdong
Department of Hematology, Dongguan People's Hospital Recruiting
Dongguan, Guangdong, China, 523059
Contact: Yirong Jiang, MD    13688967985    dgjyr0769@163.com   
Contact: Mingjun Wang, MD, PhD    15814723218    mingjunw429@163.com   
Principal Investigator: Yirong Jiang, MD         
Sponsors and Collaborators
Shenzhen Institute for Innovation and Translational Medicine
Dongguan People's Hospital
Investigators
Layout table for investigator information
Principal Investigator: Mingjun Wang, MD,PhD Shenzhen Institute for Innovation and Translational Medicine
Principal Investigator: Yirong Jiang, MD Dongguan People's Hospital

Layout table for additonal information
Responsible Party: Shenzhen Institute for Innovation and Translational Medicine
ClinicalTrials.gov Identifier: NCT03076437     History of Changes
Other Study ID Numbers: SIITM20160115
First Posted: March 10, 2017    Key Record Dates
Last Update Posted: March 10, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Fludarabine
Antineoplastic Agents